In vitro evidence to support amphotericin B and flucytosine combination therapy for talaromycosis.

ABSTRACT:

Background

Talaromyces marneffei causes talaromycosis, a life-threatening fungal disease with limited treatment options. The standard treatment of amphotericin B (AmB) induction followed by itraconazole consolidation still results in 15% to 30% mortality. This study aimed to investigate the potential of AmB and flucytosine (5FC) combination therapy to enhance antifungal activity.

Methods

The in vitro antifungal activity of AmB and 5FC alone and in combination against 60 T. marneffei clinical isolates was evaluated using a validated colorimetric antifungal susceptibility assay and the checkerboard method. The minimum inhibitory concentration (MIC) was defined as the lowest drug concentration inhibiting ≥ 95% fungal growth (MIC95) for both AmB and 5FC. The combination effect b

SUBMITTER: Natesan Sambath H 

PROVIDER: S-EPMC12782420 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature